US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Companhia Brasileira De Distribuicao

0.4450

+0.0000

Volume:- -

Turnover:- -

Market Cap:218.06M

PE:-0.26

High:0.4450

Open:0.4450

Low:0.4450

Close:0.4450

Loading ...

Overview Company News Filings

Xebra Brands Partners with BSK Holdings to Launch CBD Products in Mexico

Virpax Pharmaceuticals Announces Reverse Stock Split

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

Press Release: AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

Scott Power: ASX health sector falls as market faces gathering storm clouds

Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia

Press Release: Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Avecho Signs Licensing Agreement with Swiss Off-Patient Medicine Provider

MT Newswires Live

IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…

Zacks Small Cap Research

Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

Ethereum Investors Capitalize During Dip, Accumulating Amidst Price Decline

Xebra Brands Unveils Strategic Plan to Boost North American CBD Market Presence

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CBD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CBD\",,,,,undefined,":{"symbol":"CBD","market":"US","secType":"STK","nameCN":"Companhia Brasileira De Distribuicao","latestPrice":0.445,"timestamp":1742414400000,"preClose":0.445,"halted":4,"volume":0,"delay":0,"changeRate":0,"change":0,"floatShares":380000000,"shares":490015170,"eps":-1.733428,"lyrEps":-1.733428,"pbRate":0.23,"amount":0,"amplitude":0,"dividePrice":0.072747},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CBD\",,,,,undefined,":{"symbol":"CBD","floatShares":380000000,"roa":"0.18%","roe":"0.93%","lyrEps":-1.733428,"shares":490015170,"dividePrice":0.072747,"high":0.445,"amplitude":0,"preClose":0.445,"low":0.445,"week52Low":0.445,"pbRate":"0.23","psRate":"0.06","week52High":4.76,"institutionHeld":0.0166,"latestPrice":0.445,"eps":-1.733428,"divideRate":0.15378,"volume":0,"delay":0,"ttmEps":-1.733428,"open":0.445},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CBD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-04-19","symbol":"CBD","reason":null,"defaultRemindTime":1713533400000,"announcedDate":"2024-04-16","type":"delisting","dateTimestamp":1713499200000},{"date":"2024-02-21","symbol":"CBD","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708549200000,"name":null,"time":"Post Market","dateTimestamp":1708491600000,"actualEps":null},{"market":"US","date":"2023-10-30","symbol":"CBD","fiscalQuarterEnding":"2023/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1698638400000,"reportTimeType":"post","actualEps":0.62},{"market":"US","date":"2023-07-26","symbol":"CBD","fiscalQuarterEnding":"2023/06","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1690344000000,"reportTimeType":"post","actualEps":-0.11},{"market":"US","date":"2023-05-03","symbol":"CBD","fiscalQuarterEnding":"2023/03","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1683086400000,"reportTimeType":"post","actualEps":-0.08}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-12-08","recordDate":"2017-12-11","paymentDate":"2017-12-22","value":0.0822501,"currency":"USD"},{"executeDate":"2018-04-05","recordDate":"2018-04-06","paymentDate":"2018-06-04","value":0.090437,"currency":"USD"},{"executeDate":"2018-05-07","recordDate":"2018-05-08","paymentDate":"2018-06-19","value":0.0713349,"currency":"USD"},{"executeDate":"2018-10-04","recordDate":"2018-10-08","paymentDate":"2018-12-04","value":0.09474,"currency":"USD"},{"executeDate":"2018-12-07","recordDate":"2018-12-10","paymentDate":"2018-12-20","value":0.061204,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CBD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.6667,"sell":0.3333,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6667,"analysts":3,"updateTime":1698120000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CBD\",params:#withValueCompare:true,withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CBD","date":"2024-04-17","current":-0.530796,"percent":0.126603,"low":-25.287022,"twenty":-0.339277,"median":3.850562,"eighty":22.473332,"high":46.29902,"avg":10.700433,"sd":14.397438,"marketCap":230410252.5},"quantilePoints":[{"date":"2020-03-20","current":22.810135,"twenty":-48.946894,"median":21.588859,"eighty":25.197731,"marketCap":3594942058.61},{"date":"2020-03-27","current":21.721882,"twenty":-48.935871,"median":21.60074,"eighty":25.179903,"marketCap":3359163574.83},{"date":"2020-04-03","current":21.345261,"twenty":-48.860709,"median":21.602678,"eighty":25.159079,"marketCap":3176976595.01},{"date":"2020-04-09","current":21.477588,"twenty":-48.704907,"median":21.606025,"eighty":25.154305,"marketCap":3356669740.05},{"date":"2020-04-17","current":21.715096,"twenty":-48.702333,"median":21.609318,"eighty":25.144556,"marketCap":3263999050.19},{"date":"2020-04-24","current":22.834781,"twenty":-48.579562,"median":21.627322,"eighty":25.102652,"marketCap":3171274363.62},{"date":"2020-05-01","current":22.468339,"twenty":-48.568489,"median":21.638946,"eighty":25.078937,"marketCap":3234680852.5},{"date":"2020-05-08","current":22.325834,"twenty":-48.481355,"median":21.650944,"eighty":25.070473,"marketCap":3079156513.09},{"date":"2020-05-15","current":28.186537,"twenty":-48.447891,"median":21.667595,"eighty":25.102652,"marketCap":2538803895.94},{"date":"2020-05-22","current":29.23938,"twenty":-48.345368,"median":21.688339,"eighty":25.184811,"marketCap":2750706470.92},{"date":"2020-05-29","current":32.188361,"twenty":-48.231654,"median":21.68834,"eighty":25.26055,"marketCap":3099015407.89},{"date":"2020-06-05","current":34.161163,"twenty":-48.14463,"median":21.688342,"eighty":25.352295,"marketCap":3624012945.3},{"date":"2020-06-12","current":32.75567,"twenty":-48.054795,"median":21.698184,"eighty":27.879075,"marketCap":3385532139.93},{"date":"2020-06-19","current":34.968683,"twenty":-48.035998,"median":21.715096,"eighty":28.595408,"marketCap":3427981597.1},{"date":"2020-06-26","current":35.168008,"twenty":-48.035998,"median":21.71633,"eighty":29.911371,"marketCap":3360143701.29},{"date":"2020-07-02","current":36.45084,"twenty":-48.022113,"median":21.724637,"eighty":29.911371,"marketCap":3589326172.62},{"date":"2020-07-10","current":36.133965,"twenty":-48.001657,"median":21.739192,"eighty":30.481044,"marketCap":3535203761.27},{"date":"2020-07-17","current":36.338401,"twenty":-47.984158,"median":21.763698,"eighty":30.859866,"marketCap":3565189761.84},{"date":"2020-07-24","current":38.280538,"twenty":-47.948952,"median":21.784625,"eighty":31.119719,"marketCap":3861361680.14},{"date":"2020-07-31","current":43.116873,"twenty":-47.824902,"median":21.808485,"eighty":31.478495,"marketCap":3665807009.06},{"date":"2020-08-07","current":41.264669,"twenty":-47.722877,"median":21.825044,"eighty":32.697406,"marketCap":3354170959.93},{"date":"2020-08-14","current":39.849707,"twenty":-47.666426,"median":21.837479,"eighty":33.328089,"marketCap":3260128153.23},{"date":"2020-08-21","current":39.260646,"twenty":-47.51716,"median":21.870315,"eighty":33.856936,"marketCap":3080279792.74},{"date":"2020-08-28","current":39.655377,"twenty":-47.41864,"median":21.887014,"eighty":34.083478,"marketCap":3208399190.93},{"date":"2020-09-04","current":38.422599,"twenty":-47.338661,"median":21.926444,"eighty":34.212124,"marketCap":3196869287.59},{"date":"2020-09-11","current":45.048023,"twenty":-47.290874,"median":21.938573,"eighty":34.320751,"marketCap":3752796369.65},{"date":"2020-09-18","current":45.728176,"twenty":-47.27367,"median":21.951723,"eighty":34.513814,"marketCap":3809097848.59},{"date":"2020-09-25","current":44.963004,"twenty":-47.072164,"median":21.961478,"eighty":34.75322,"marketCap":3559204588.14},{"date":"2020-10-02","current":41.641183,"twenty":-46.802882,"median":21.972505,"eighty":34.938716,"marketCap":3252756411.36},{"date":"2020-10-09","current":41.082485,"twenty":-46.779299,"median":21.985911,"eighty":35.057852,"marketCap":3277798562.59},{"date":"2020-10-16","current":40.432696,"twenty":-46.70731,"median":22.002099,"eighty":35.161764,"marketCap":3165365221.28},{"date":"2020-10-23","current":40.31124,"twenty":-46.644009,"median":22.012655,"eighty":35.497149,"marketCap":3159109473.64},{"date":"2020-10-30","current":24.644689,"twenty":-46.604291,"median":22.01955,"eighty":35.648431,"marketCap":2896998479.69},{"date":"2020-11-06","current":26.13252,"twenty":-46.532302,"median":22.020887,"eighty":35.497149,"marketCap":3223343947.99},{"date":"2020-11-13","current":27.68798,"twenty":-46.503754,"median":22.034906,"eighty":35.382906,"marketCap":3389215469.83},{"date":"2020-11-20","current":29.040553,"twenty":-46.449142,"median":22.046559,"eighty":35.313901,"marketCap":3635935746.48},{"date":"2020-11-27","current":27.628307,"twenty":-46.369706,"median":22.054395,"eighty":35.247479,"marketCap":3486907168.56},{"date":"2020-12-04","current":28.133533,"twenty":-46.281582,"median":22.056607,"eighty":35.164886,"marketCap":3665429793.94},{"date":"2020-12-11","current":28.96099,"twenty":-46.240622,"median":22.086319,"eighty":35.146652,"marketCap":3868889329.47},{"date":"2020-12-18","current":29.556023,"twenty":-46.213316,"median":22.095193,"eighty":35.120788,"marketCap":3915243567.22},{"date":"2020-12-24","current":28.923532,"twenty":-46.203386,"median":22.104636,"eighty":35.109294,"marketCap":3740877414.61},{"date":"2020-12-31","current":29.854367,"twenty":-46.197877,"median":22.112569,"eighty":35.074809,"marketCap":3874652170.15},{"date":"2021-01-08","current":30.447079,"twenty":-46.187114,"median":22.13219,"eighty":35.049515,"marketCap":3813098087.07},{"date":"2021-01-15","current":30.399344,"twenty":-46.160708,"median":22.135814,"eighty":35.01834,"marketCap":3903142794.22},{"date":"2021-01-22","current":29.997573,"twenty":-45.994275,"median":22.153559,"eighty":35.009864,"marketCap":3703200569.99},{"date":"2021-01-29","current":30.025418,"twenty":-45.853549,"median":22.186693,"eighty":34.984695,"marketCap":3697900820.09},{"date":"2021-02-05","current":33.852187,"twenty":-45.79947,"median":22.196627,"eighty":34.923733,"marketCap":4261079136.63},{"date":"2021-02-12","current":35.383691,"twenty":-45.750413,"median":22.223172,"eighty":34.970795,"marketCap":4444806168.48},{"date":"2021-02-19","current":35.383691,"twenty":-45.719321,"median":22.27447,"eighty":34.994814,"marketCap":4436867685.62},{"date":"2021-02-26","current":10.212638,"twenty":-45.678501,"median":22.237271,"eighty":34.994814,"marketCap":3990270236.33},{"date":"2021-03-05","current":2.818934,"twenty":-45.622717,"median":22.199746,"eighty":34.971852,"marketCap":1076849552.95},{"date":"2021-03-12","current":3.063791,"twenty":-45.574102,"median":22.186927,"eighty":34.967613,"marketCap":1199856474.48},{"date":"2021-03-19","current":3.483371,"twenty":-45.526936,"median":22.155315,"eighty":34.937111,"marketCap":1390464034.77},{"date":"2021-03-26","current":3.864807,"twenty":-45.464876,"median":22.135814,"eighty":34.874928,"marketCap":1474156501.13},{"date":"2021-04-01","current":3.974316,"twenty":-45.427641,"median":22.13219,"eighty":34.845744,"marketCap":1524251337.85},{"date":"2021-04-09","current":4.146577,"twenty":-45.422547,"median":22.115469,"eighty":34.837397,"marketCap":1598703307.85},{"date":"2021-04-16","current":4.499713,"twenty":-45.383682,"median":22.104636,"eighty":34.813697,"marketCap":1748185711.23},{"date":"2021-04-23","current":4.694122,"twenty":-45.303561,"median":22.094549,"eighty":34.789444,"marketCap":1858576905.55},{"date":"2021-04-30","current":5.011575,"twenty":-45.254059,"median":22.074748,"eighty":34.763845,"marketCap":2010979579.4},{"date":"2021-05-07","current":4.058571,"twenty":-45.09512,"median":22.054395,"eighty":34.717768,"marketCap":1893864684.18},{"date":"2021-05-14","current":4.02764,"twenty":-44.784719,"median":22.052698,"eighty":34.681178,"marketCap":1862032146.94},{"date":"2021-05-21","current":3.908335,"twenty":-44.471923,"median":22.043522,"eighty":34.588005,"marketCap":1785459269.48},{"date":"2021-05-28","current":4.307122,"twenty":-44.361415,"median":22.03038,"eighty":34.562337,"marketCap":2005690908.74},{"date":"2021-06-04","current":4.612012,"twenty":-44.316569,"median":22.020601,"eighty":34.524036,"marketCap":2207173362.19},{"date":"2021-06-11","current":4.270668,"twenty":-44.037505,"median":22.018832,"eighty":34.498482,"marketCap":2021578655.43},{"date":"2021-06-18","current":4.134793,"twenty":-44.037505,"median":22.008336,"eighty":34.474206,"marketCap":1991763627.07},{"date":"2021-06-25","current":4.286133,"twenty":-43.441733,"median":22.000698,"eighty":34.45409,"marketCap":2109413263.72},{"date":"2021-07-02","current":4.331425,"twenty":-43.441733,"median":21.984466,"eighty":34.333395,"marketCap":2092076937.36},{"date":"2021-07-09","current":4.095025,"twenty":-43.004833,"median":21.972505,"eighty":34.308106,"marketCap":1893581139.1},{"date":"2021-07-16","current":3.969092,"twenty":-42.895608,"median":21.961478,"eighty":34.27307,"marketCap":1894941520.42},{"date":"2021-07-23","current":3.745948,"twenty":-6.477533,"median":21.951723,"eighty":34.247528,"marketCap":1760925049.97},{"date":"2021-07-30","current":3.978786,"twenty":2.717546,"median":21.938573,"eighty":34.227943,"marketCap":1621707866.52},{"date":"2021-08-06","current":3.8839,"twenty":2.774638,"median":21.919621,"eighty":34.208101,"marketCap":1560369446.85},{"date":"2021-08-13","current":3.896722,"twenty":2.805892,"median":21.884477,"eighty":34.186101,"marketCap":1565011651.84},{"date":"2021-08-20","current":3.771063,"twenty":2.817458,"median":21.859881,"eighty":34.165252,"marketCap":1466097684.02},{"date":"2021-08-27","current":3.741572,"twenty":2.860277,"median":21.833211,"eighty":34.103921,"marketCap":1508298368.32},{"date":"2021-09-03","current":3.476148,"twenty":2.907034,"median":21.820707,"eighty":34.081433,"marketCap":1409258362.72},{"date":"2021-09-10","current":3.504357,"twenty":2.989227,"median":21.808485,"eighty":34.014541,"marketCap":1408830778.38},{"date":"2021-09-17","current":3.397932,"twenty":3.048288,"median":21.784625,"eighty":33.952342,"marketCap":1343579732.88},{"date":"2021-09-24","current":3.521027,"twenty":3.060346,"median":21.763698,"eighty":33.908662,"marketCap":1382952193.26},{"date":"2021-10-01","current":3.215854,"twenty":3.063791,"median":21.739192,"eighty":33.866501,"marketCap":1255875055.07},{"date":"2021-10-08","current":3.154306,"twenty":3.063791,"median":21.724637,"eighty":33.842622,"marketCap":1200153926.26},{"date":"2021-10-15","current":3.96981,"twenty":3.063791,"median":21.71526,"eighty":33.822672,"marketCap":1531142618.11},{"date":"2021-10-22","current":3.373569,"twenty":3.071174,"median":21.708983,"eighty":33.580567,"marketCap":1232292380.31},{"date":"2021-10-29","current":3.273555,"twenty":3.076096,"median":21.698132,"eighty":33.366932,"marketCap":1217907595.63},{"date":"2021-11-05","current":3.845374,"twenty":3.123022,"median":21.688342,"eighty":33.328089,"marketCap":1129948802.72},{"date":"2021-11-12","current":3.891784,"twenty":3.18508,"median":21.688339,"eighty":33.315562,"marketCap":1163009235.06},{"date":"2021-11-19","current":3.78902,"twenty":3.211751,"median":21.681076,"eighty":33.25534,"marketCap":1106482078.87},{"date":"2021-11-26","current":3.837087,"twenty":3.223547,"median":21.662422,"eighty":33.169651,"marketCap":1112318238.91},{"date":"2021-12-03","current":3.72935,"twenty":3.238677,"median":21.645183,"eighty":32.958061,"marketCap":1071011813.12},{"date":"2021-12-10","current":3.825485,"twenty":3.255347,"median":21.63604,"eighty":32.716827,"marketCap":1110143830.28},{"date":"2021-12-17","current":3.853662,"twenty":3.272785,"median":21.622964,"eighty":32.642749,"marketCap":1102928442.1},{"date":"2021-12-23","current":3.677968,"twenty":3.277145,"median":21.609318,"eighty":32.594366,"marketCap":1048082133.18},{"date":"2021-12-31","current":3.601724,"twenty":3.292275,"median":21.601682,"eighty":32.434243,"marketCap":1049805090.19},{"date":"2022-01-07","current":3.140942,"twenty":3.277145,"median":21.589375,"eighty":32.088086,"marketCap":903195899.14},{"date":"2022-01-14","current":3.300061,"twenty":3.256049,"median":21.564027,"eighty":31.667338,"marketCap":965987440.7},{"date":"2022-01-21","current":3.232103,"twenty":3.251993,"median":21.559272,"eighty":31.588745,"marketCap":969377362.76},{"date":"2022-01-28","current":3.586806,"twenty":3.258623,"median":21.550394,"eighty":31.51707,"marketCap":1079398343.74},{"date":"2022-02-04","current":3.565259,"twenty":3.272272,"median":21.535968,"eighty":31.452778,"marketCap":1084326882.6},{"date":"2022-02-11","current":3.571889,"twenty":3.287916,"median":21.506499,"eighty":31.382975,"marketCap":1118065476.08},{"date":"2022-02-18","current":3.505589,"twenty":3.302797,"median":21.506499,"eighty":31.382975,"marketCap":1109826465.49},{"date":"2022-02-25","current":7.821349,"twenty":3.320997,"median":21.506499,"eighty":31.382975,"marketCap":1215997202.48},{"date":"2022-03-04","current":8.046254,"twenty":3.34415,"median":21.506499,"eighty":31.382975,"marketCap":1268820850.98},{"date":"2022-03-11","current":7.43196,"twenty":3.40819,"median":21.506499,"eighty":31.382975,"marketCap":1181242507.38},{"date":"2022-03-18","current":7.677006,"twenty":3.455049,"median":21.506499,"eighty":31.382975,"marketCap":1229154717.61},{"date":"2022-03-25","current":8.331582,"twenty":3.475635,"median":21.506499,"eighty":31.382975,"marketCap":1404091104.25},{"date":"2022-04-01","current":8.432287,"twenty":3.52513,"median":21.506499,"eighty":31.382975,"marketCap":1438779186.86},{"date":"2022-04-08","current":8.577252,"twenty":3.543033,"median":21.506499,"eighty":31.382975,"marketCap":1447013224.09},{"date":"2022-04-14","current":8.009911,"twenty":3.569366,"median":21.506499,"eighty":31.382975,"marketCap":1364475125.11},{"date":"2022-04-22","current":7.489569,"twenty":3.589575,"median":21.506499,"eighty":31.382975,"marketCap":1262587657.75},{"date":"2022-04-29","current":6.824874,"twenty":3.604376,"median":21.506499,"eighty":31.382975,"marketCap":1107714381.64},{"date":"2022-05-06","current":2.682632,"twenty":3.611792,"median":21.506499,"eighty":31.382975,"marketCap":1111684830.71},{"date":"2022-05-13","current":2.754856,"twenty":3.611792,"median":21.506499,"eighty":31.382975,"marketCap":1134186522.2},{"date":"2022-05-20","current":2.638781,"twenty":3.611792,"median":21.506499,"eighty":31.382975,"marketCap":1131812185.86},{"date":"2022-05-27","current":2.674893,"twenty":3.611792,"median":21.506499,"eighty":31.382975,"marketCap":1183425678.78},{"date":"2022-06-03","current":2.552369,"twenty":3.611792,"median":21.506499,"eighty":31.382975,"marketCap":1110303814.25},{"date":"2022-06-10","current":2.534313,"twenty":3.611792,"median":21.506499,"eighty":31.382975,"marketCap":1058456211.35},{"date":"2022-06-17","current":2.307321,"twenty":3.611792,"median":21.506499,"eighty":31.382975,"marketCap":937548525.28},{"date":"2022-06-24","current":2.142236,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":855566898.49},{"date":"2022-07-01","current":2.155134,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":846454008.13},{"date":"2022-07-08","current":2.297003,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":905872746.25},{"date":"2022-07-15","current":2.033899,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":789159239.97},{"date":"2022-07-22","current":2.179638,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":834005541.61},{"date":"2022-07-29","current":2.295975,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":847767919.28},{"date":"2022-08-05","current":2.317091,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":850443210.61},{"date":"2022-08-12","current":2.615526,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":983102539.54},{"date":"2022-08-19","current":2.667611,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":980185450.32},{"date":"2022-08-26","current":2.885806,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":1082099437.44},{"date":"2022-09-02","current":3.040654,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":1122192220.74},{"date":"2022-09-09","current":3.094147,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":1147824860.77},{"date":"2022-09-16","current":2.992792,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":1084422932.1},{"date":"2022-09-23","current":2.966045,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":1083970737.99},{"date":"2022-09-30","current":2.72955,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":964761941.3},{"date":"2022-10-07","current":2.726735,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":1000430263.52},{"date":"2022-10-14","current":2.776005,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":1000979516.71},{"date":"2022-10-21","current":2.982938,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":1098306302.06},{"date":"2022-10-28","current":2.967453,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":1064015927.61},{"date":"2022-11-04","current":3.247127,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":1098494722.08},{"date":"2022-11-11","current":3.122298,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":1002133691.8},{"date":"2022-11-18","current":2.85368,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":908431927.94},{"date":"2022-11-25","current":2.885282,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":918834988.71},{"date":"2022-12-02","current":3.054354,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":996963123.45},{"date":"2022-12-09","current":2.901083,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":946644658.58},{"date":"2022-12-16","current":2.585061,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":837135566.52},{"date":"2022-12-23","current":2.84911,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":947463359},{"date":"2022-12-30","current":2.614331,"twenty":3.618298,"median":21.521265,"eighty":31.400426,"marketCap":843651604.06},{"date":"2023-01-06","current":2.644399,"twenty":3.601724,"median":21.477588,"eighty":31.119719,"marketCap":858453441.92},{"date":"2023-01-13","current":2.908681,"twenty":3.586143,"median":21.451779,"eighty":30.859866,"marketCap":973593039.16},{"date":"2023-01-20","current":3.030535,"twenty":3.568501,"median":21.434094,"eighty":30.595809,"marketCap":993923644.58},{"date":"2023-01-27","current":3.146059,"twenty":3.54196,"median":21.419363,"eighty":30.382636,"marketCap":1054041062.84},{"date":"2023-02-03","current":2.992554,"twenty":3.524104,"median":21.399225,"eighty":30.008711,"marketCap":996136217.24},{"date":"2023-02-10","current":2.880195,"twenty":3.475122,"median":21.367263,"eighty":29.937896,"marketCap":936889911.72},{"date":"2023-02-17","current":2.753593,"twenty":3.454233,"median":21.345222,"eighty":29.911371,"marketCap":905113552.53},{"date":"2023-02-24","current":2.649146,"twenty":3.413831,"median":21.285001,"eighty":29.854367,"marketCap":871184511.25},{"date":"2023-03-03","current":-22.618621,"twenty":3.347449,"median":21.254854,"eighty":29.454983,"marketCap":746732732.87},{"date":"2023-03-10","current":-21.818101,"twenty":3.322536,"median":21.189233,"eighty":29.093988,"marketCap":725119970.24},{"date":"2023-03-17","current":-22.100638,"twenty":3.302218,"median":21.158238,"eighty":28.921145,"marketCap":720996466.44},{"date":"2023-03-24","current":-21.504172,"twenty":3.288292,"median":21.095203,"eighty":28.536529,"marketCap":703847289.44},{"date":"2023-03-31","current":-23.120909,"twenty":3.273298,"median":21.041465,"eighty":28.389727,"marketCap":785384865.61},{"date":"2023-04-06","current":-22.728497,"twenty":3.251398,"median":21.025295,"eighty":28.119338,"marketCap":771400099.06},{"date":"2023-04-14","current":-23.811553,"twenty":3.237546,"median":20.922967,"eighty":27.766747,"marketCap":834845936.24},{"date":"2023-04-20","current":-23.356356,"twenty":3.217453,"median":20.902351,"eighty":27.544766,"marketCap":796528833.94},{"date":"2023-04-28","current":-22.822675,"twenty":3.199725,"median":20.844028,"eighty":26.562161,"marketCap":784315721.28},{"date":"2023-05-05","current":-2.230781,"twenty":3.16382,"median":20.742059,"eighty":26.056139,"marketCap":808195921.17},{"date":"2023-05-12","current":-2.410371,"twenty":3.145036,"median":20.649113,"eighty":25.34307,"marketCap":882701200.1},{"date":"2023-05-19","current":-2.585509,"twenty":3.118821,"median":20.58782,"eighty":25.205155,"marketCap":946476312.94},{"date":"2023-05-26","current":-2.41334,"twenty":3.091561,"median":20.54624,"eighty":25.111033,"marketCap":876098093.68},{"date":"2023-06-02","current":-2.462319,"twenty":3.075483,"median":20.515941,"eighty":25.061974,"marketCap":890856239.23},{"date":"2023-06-09","current":-2.529109,"twenty":3.062068,"median":20.482836,"eighty":25.015616,"marketCap":934347875.58},{"date":"2023-06-16","current":-2.640425,"twenty":3.040114,"median":20.436362,"eighty":24.868624,"marketCap":998925390.49},{"date":"2023-06-23","current":-2.585509,"twenty":3.032434,"median":20.394921,"eighty":24.803209,"marketCap":984806264.97},{"date":"2023-06-30","current":-2.710183,"twenty":3.011273,"median":20.294379,"eighty":24.717317,"marketCap":1013949707.53},{"date":"2023-07-07","current":-2.98328,"twenty":2.986784,"median":20.206669,"eighty":24.644689,"marketCap":1105345976.7},{"date":"2023-07-14","current":-3.165838,"twenty":2.968715,"median":20.174382,"eighty":24.547654,"marketCap":1195660605.65},{"date":"2023-07-21","current":-3.231144,"twenty":2.952196,"median":20.029818,"eighty":24.430089,"marketCap":1225132593.07},{"date":"2023-07-28","current":-4.731825,"twenty":2.919597,"median":19.965347,"eighty":24.315925,"marketCap":1222660247.17},{"date":"2023-08-04","current":-2.694579,"twenty":2.907914,"median":19.894303,"eighty":24.178468,"marketCap":1144477806.4},{"date":"2023-08-11","current":-2.643738,"twenty":2.894114,"median":19.841226,"eighty":24.141856,"marketCap":1129648804.57},{"date":"2023-08-18","current":-2.502947,"twenty":2.880195,"median":19.711908,"eighty":24.108655,"marketCap":1039673491.92},{"date":"2023-08-25","current":-0.829101,"twenty":2.865372,"median":11.114549,"eighty":24.005884,"marketCap":351858372.13},{"date":"2023-09-01","current":-0.643988,"twenty":2.850423,"median":8.637679,"eighty":23.866588,"marketCap":270198163.9},{"date":"2023-09-08","current":-0.607486,"twenty":2.827809,"median":8.432287,"eighty":23.866588,"marketCap":252748038.25},{"date":"2023-09-15","current":-0.597057,"twenty":2.810384,"median":8.265047,"eighty":23.866588,"marketCap":253709822.11},{"date":"2023-09-22","current":-0.473213,"twenty":2.801487,"median":8.073695,"eighty":23.631664,"marketCap":199370402.19},{"date":"2023-09-29","current":-0.438016,"twenty":2.782281,"median":7.976341,"eighty":23.486816,"marketCap":179982682.09},{"date":"2023-10-06","current":-0.430194,"twenty":2.773105,"median":7.821349,"eighty":23.289799,"marketCap":172107552.06},{"date":"2023-10-13","current":-0.470606,"twenty":2.757959,"median":7.720645,"eighty":23.153989,"marketCap":193083099.43},{"date":"2023-10-20","current":-0.452356,"twenty":2.753526,"median":7.5998,"eighty":23.092341,"marketCap":185676037.66},{"date":"2023-10-27","current":-0.451052,"twenty":2.739251,"median":7.516152,"eighty":22.999423,"marketCap":186575719.34},{"date":"2023-11-03","current":-0.313071,"twenty":2.718898,"median":7.226041,"eighty":22.999423,"marketCap":193994548.68},{"date":"2023-11-10","current":-0.327141,"twenty":2.682443,"median":5.918224,"eighty":22.999423,"marketCap":204846881.99},{"date":"2023-11-17","current":-0.344729,"twenty":2.665456,"median":4.823933,"eighty":22.999423,"marketCap":216953151.64},{"date":"2023-11-24","current":-0.322744,"twenty":2.64883,"median":4.733496,"eighty":22.999423,"marketCap":202581133.51},{"date":"2023-12-01","current":-0.294603,"twenty":2.638523,"median":4.617999,"eighty":22.999423,"marketCap":183398747.44},{"date":"2023-12-08","current":-0.3588,"twenty":2.626986,"median":4.476137,"eighty":22.987251,"marketCap":224400731.35},{"date":"2023-12-15","current":-0.355282,"twenty":2.615526,"median":4.439421,"eighty":22.987251,"marketCap":223064133.79},{"date":"2023-12-22","current":-0.34385,"twenty":2.585061,"median":4.338053,"eighty":22.987251,"marketCap":216790786.15},{"date":"2023-12-29","current":-0.357041,"twenty":2.549274,"median":4.312646,"eighty":22.999423,"marketCap":226526469.79},{"date":"2024-01-05","current":-0.391338,"twenty":2.530186,"median":4.286133,"eighty":23.011594,"marketCap":244710915.78},{"date":"2024-01-12","current":-0.322744,"twenty":2.393058,"median":4.270668,"eighty":22.991819,"marketCap":202917185.28},{"date":"2024-01-19","current":-0.383423,"twenty":2.339614,"median":4.182294,"eighty":22.832408,"marketCap":238305515.94},{"date":"2024-01-26","current":-0.360559,"twenty":2.303346,"median":4.140317,"eighty":22.753392,"marketCap":224996535.97},{"date":"2024-02-02","current":-0.367594,"twenty":2.254589,"median":4.110573,"eighty":22.623113,"marketCap":229307475.11},{"date":"2024-02-09","current":-0.351765,"twenty":2.18944,"median":4.082594,"eighty":22.559051,"marketCap":216242995.59},{"date":"2024-02-16","current":-0.336815,"twenty":2.154102,"median":4.042001,"eighty":22.486982,"marketCap":207843422.11},{"date":"2024-02-23","current":-0.473147,"twenty":2.142236,"median":4.016151,"eighty":22.473332,"marketCap":217328977.79},{"date":"2024-03-01","current":-0.479092,"twenty":2.106382,"median":3.97557,"eighty":22.470836,"marketCap":218683677.57},{"date":"2024-03-08","current":-0.42084,"twenty":2.009395,"median":3.962464,"eighty":22.470836,"marketCap":193717975.72},{"date":"2024-03-15","current":-0.707676,"twenty":-0.300407,"median":3.942643,"eighty":22.470836,"marketCap":322872943.99},{"date":"2024-03-22","current":-0.664525,"twenty":-0.313071,"median":3.90317,"eighty":22.470836,"marketCap":303325727.09},{"date":"2024-03-28","current":-0.655895,"twenty":-0.323623,"median":3.891784,"eighty":22.470836,"marketCap":297806208.89},{"date":"2024-04-05","current":-0.591212,"twenty":-0.332242,"median":3.876867,"eighty":22.473332,"marketCap":267997677.6},{"date":"2024-04-12","current":-0.561004,"twenty":-0.336815,"median":3.864807,"eighty":22.473332,"marketCap":250499300.43},{"date":"2024-04-17","current":-0.530796,"twenty":-0.339277,"median":3.850562,"eighty":22.473332,"marketCap":230410252.5}],"customCompares":[],"updateTime":1742413049494},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CBD\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520134235","title":"Xebra Brands Partners with BSK Holdings to Launch CBD Products in Mexico","url":"https://stock-news.laohu8.com/highlight/detail?id=2520134235","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520134235?lang=en_us&edition=fundamental","pubTime":"2025-03-19 22:08","pubTimestamp":1742393300,"startTime":"0","endTime":"0","summary":"The latest update is out from Xebra Brands Ltd. ( ($TSE:XBRA) ). Xebra Brands Ltd. has announced a strategic partnership with BSK Holdings Inc. to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xebra-brands-partners-with-bsk-holdings-to-launch-cbd-products-in-mexico?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xebra-brands-partners-with-bsk-holdings-to-launch-cbd-products-in-mexico?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CBD","ACB","BK4007","BK4557","BK4113"],"gpt_icon":0},{"id":"2520186615","title":"Virpax Pharmaceuticals Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2520186615","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520186615?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:00","pubTimestamp":1742385600,"startTime":"0","endTime":"0","summary":"BERWYN, Pa., March 19, 2025----Virpax Pharmaceuticals, Inc.   a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system  disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split  of its common stock, par value $0.0001 per share , that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market  under the symbol \"VRPX\" and will begin trading on a split-adjusted basis when the Nasdaq opens on March 21, 2025 . The new CUSIP number for the Common Stock following the reverse split will be 928251305.The Company’s transfer agent, VStock Transfer, LLC, which is also acting as the paying agent for the reverse split, will provide instructions to stockholders regarding the process for exchanging stock certificates. Any person who would otherwise be entitled to a fr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/virpax-pharmaceuticals-announces-reverse-stock-120000254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","BK4588","QLD","BK4585","BK4162","MET","CBD","LU1989772840.SGD","BK4135","PSQ","DOD","LU1496350502.SGD","TSYW.SI","VRPX","CNS","MNQmain","NQmain","BK4113","LU1989772923.USD","LU1291159041.SGD","NVIW.SI","USJW.SI","QID","IE00B29SXL02.USD","LU1989771016.USD","TQQQ","USAW.SI","IE00B29SXK94.USD",".IXIC"],"gpt_icon":1},{"id":"2520352170","title":"TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2520352170","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520352170?lang=en_us&edition=fundamental","pubTime":"2025-03-17 21:15","pubTimestamp":1742217300,"startTime":"0","endTime":"0","summary":"Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle loss. BALTIMORE, March 17, 2025----TNF Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced that data from the Phase 2a clinical trial of its oral TNF-alpha  inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th International Conference on Frailty and Sarcopenia Research  held March 12-14, 2025, in Toulouse, France.The presentation included positive Phase 2a clinical data showing decreases of biomarkers associated with TNF-α activation in elderly patients with sarcopenia. The Company’s recently initiated Phase 2b clinical trial will further evaluate isomyosamine as a treatment for chronic inflammation associated with muscle loss  in patients who have undergone hip or femur fracture re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-delivers-podium-presentation-131500702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4557","CBD","ACB","BK4113","TNFA","BK4007"],"gpt_icon":0},{"id":"2519887682","title":"Press Release: AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887682","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887682?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"-- Landmark exclusive option and license deal with Takeda for ACI-24.060. with $100 million upfront and additional potential milestones of up to. about $2.1 billion plus royalties on sales upon commercialization. -- ACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and. tolerability data in Down syndrome  cohort; further interim results. in Alzheimer's disease  and DS expected in 2025. -- Enrollment progress in JNJ-2056  ReTain Phase 2b trial in. preclinical AD patients triggered second milestone payment of CHF 24.6. -- ACI-7104.056 VacSYn Phase 2 trial demonstrated positive interim safety. and immunogenicity results in Parkinson's disease ; further interim. \"The ability to innovate is key to our future success. Driven by our two drug discovery platforms, in 2024, we advanced multiple early-stage asse","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BSNM7G36.USD","LU0320765646.SGD","SG9999002224.SGD","LU0640476718.USD","LU1244550494.USD","IE000M9KFDE8.USD","LU0792757196.USD","AAIC","LU2089984988.USD","BK4604","03160","TM","LU0203345920.USD","JNJ","LU1032466523.USD","LU1059921491.USD","BK4532","LU1778281490.HKD","CBD","R","IE00BDGV0183.EUR","LU1162221912.USD","IE0009355771.USD","IE00B4R5TH58.HKD","PSP","AC","BK4581","LU0114720955.EUR","LU1169589451.USD","LU1506573853.SGD","LU0234572021.USD","BK4592","LU0098860793.USD","LU1221951129.SGD","PET","IE00B2B36J28.USD","IE00B42XCP33.USD","ACI","LU0345769128.USD","LU1244550577.SGD","LU2505996509.AUD","LU2430703095.HKD","BK4555","LU0912757837.SGD","ACIU","ARIA","IE00BVYPNV92.GBP","PD","LU0234570918.USD"],"gpt_icon":0},{"id":"2517803834","title":"Virpax Looking to Use MET to Develop Intranasal COVID Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2517803834","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517803834?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"BERWYN, Pa., March 07, 2025----Virpax Pharmaceuticals, Inc.  , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system  disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology  or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta  and NobrXiol .NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach. Enkephalin is a naturally occurring  peptide that is not easily administered in its original form. We believe that the nanotechnology may enable and enhance the delivery of this metabolically labile peptide drug into the brain. In addition, Virpax uses MET with NobrXiol. NobrXiol is being developed for delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utilizes the MET as its delivery system to cross the blood brain barrier, propelling the cannabidiol nanoparti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/virpax-looking-met-develop-intranasal-130000933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B29SXK94.USD","BK4585","BK4162","LU1989772923.USD","CNS","VRPX","LU1496350502.SGD","BK4135","LU1989772840.SGD","LU1291159041.SGD","CBD","IE00B29SXL02.USD","BK4588","BK4113","LU1989771016.USD","DOD","MET"],"gpt_icon":0},{"id":"2517278271","title":"Scott Power: ASX health sector falls as market faces gathering storm clouds","url":"https://stock-news.laohu8.com/highlight/detail?id=2517278271","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517278271?lang=en_us&edition=fundamental","pubTime":"2025-03-07 13:15","pubTimestamp":1741324522,"startTime":"0","endTime":"0","summary":"ASX health stocks fell 0.43% over the past week, while the broader market 2.51%. ProMedicus has signed a seven-year, $40 million deal with leading US radiology provider LucidHealth. Opthea falls following release of half-year results as it awaits countdown to topline phase III trial data","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/03/GettyImages-1687716975-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/03/GettyImages-1687716975-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/scott-power-asx-health-sector-falls-as-market-faces-gathering-storm-clouds/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["IE00BMPRXN33.USD","LU0889565833.HKD","BK4139","CBD","LU2098885051.SGD","TGA","LU2054465674.USD","BK4141","LU0719512351.SGD","LU2250418816.HKD","LU0823421333.USD","LU0198837287.USD","BK4529","LU1242518931.SGD","BK4585","LU0056508442.USD","IE0009356076.USD","BK4575","LU0127658192.USD","FSGS","BK4543","OPT","BK4234","BK4512","LU1923623000.USD","BK4213","IE00B5949003.HKD","LU0823434740.USD","LU0081259029.USD","LU1988902786.USD","LU2264538146.SGD","LU1316542783.SGD","LU2458330243.SGD","LU2458330169.SGD","BK4534","LU1303367103.USD","LU1803068979.SGD","BK4588","BK4605","LU1951198990.SGD","BK4573","LU1880398554.USD","BK4084","HIE","IE0004445239.USD","PW","LU1064131342.USD","BK4566","BK4532"],"gpt_icon":1},{"id":"2517243679","title":"Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS","url":"https://stock-news.laohu8.com/highlight/detail?id=2517243679","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517243679?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:01","pubTimestamp":1741208460,"startTime":"0","endTime":"0","summary":"BERWYN, Pa., March 05, 2025----Virpax Pharmaceuticals, Inc.  , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system  disorders and anti-viral barrier indications, is pleased to announce its NES100 dose range finding toxicity study will be presented at The Society of Toxicology  64th annual meeting and Tox Expo taking place March 16-20th in Orlando, FL. This is a premier gathering of scientists and professionals in the field of toxicology to advance science in this area.Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta is an intranasal molecular en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/virpax-nes100-presented-society-toxicology-210100662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","CBD","BK4585","BK4113","BK4588","IE00B29SXK94.USD","MET","LU1989772840.SGD","LU1291159041.SGD","CNS","IE00B29SXL02.USD","LU1989772923.USD","VRPX","BK4162","LU1989771016.USD","DOD","LU1496350502.SGD"],"gpt_icon":0},{"id":"2517191086","title":"TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517191086","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517191086?lang=en_us&edition=fundamental","pubTime":"2025-03-05 22:00","pubTimestamp":1741183200,"startTime":"0","endTime":"0","summary":"Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss. Investors invited to submit questions prior to the event. BALTIMORE, March 05, 2025----TNF Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer of TNF, will provide a clinical scientific update on the Company’s lead candidate isomyosamine, a novel oral TNF-alpha  inhibitor drug shown to positively impact conditions related to immunometabolic dysregulation.A Phase 2b clinical trial is currently underway to evaluate isomyosamine as a treatment for chronic inflammation associated with muscle loss  in patients who have undergone hip or femur fracture repair surge","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-host-investor-conference-140000460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","CBD","ACB","BK4007","BK4557","TNFA","BK4113","BK4585","HST","BK4218","BK4181"],"gpt_icon":0},{"id":"2516661616","title":"Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661616","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:00","pubTimestamp":1741039200,"startTime":"0","endTime":"0","summary":"Avecho and Sandoz sign an exclusive ten-year development and license agreement  for Avecho's pharmaceutical cannabidiol capsule for insomnia in Australia. Avecho to receive upfront, milestone and royalty payments:. US$16M in development milestones prior to commercial sales. Tiered royalties ranging from 14% to 19% on net sales. Sandoz to purchase the product from Avecho for commercial sale. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a right of first refusal to exceed any commercial offers Avecho receives. Avecho CEO, Dr Paul Gavin, said: \"We are excited to announce this partnership with Sandoz, which underscores the commercial potential of Avecho's drug delivery platform and our shared commitment to deliver innovative insomnia treatments. Nearly 9.5 million Australians experience symptoms of insomnia with approximately 3.6 million of those considered chronic[3]. Sandoz's extensive reach and expertise in the Australian market wil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/avecho-sandoz-enter-exclusive-license-220000509.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avecho-sandoz-enter-exclusive-license-220000509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CBD","XAO.AU","BK4588","XKO.AU","LU0683600562.USD","LU1894683264.USD","BK4533","BK4007","BK4557","ACB","BK4512","LU1093756168.USD","XJO.AU","AVE.AU","BK4534","MMM","BK4113","BK4206","LU1894683348.USD","LU0787776722.HKD","BK7096","LU1093756325.SGD","BK4585"],"gpt_icon":0},{"id":"2516339996","title":"Press Release: Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516339996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516339996?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"SOLANA BEACH, Calif., March 03, 2025  -- Artelo Biosciences, Inc. , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ended December 31, 2024.-- ART26.12: Phase I study is on track for completion in Q2 2025.-- ART27.13: Initial data from the Phase 2 CAReS trial anticipated by the. \"Each of our programs is slated to reach important clinical milestones in 2025,\" said Gregory D. Gorgas, President and CEO of Artelo Biosciences. \"Notably, enrollment in our Phase 1 study of ART26.12, a Fatty Acid Binding Protein  inhibitor, has progressed rapidly and is expected to conclude in the second quarter of this year. Designed to harness the power of lipid signaling with broad therapeutic potential, ART26.12 is the first selective FABP5 inhibitor from our propri","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","FABP","ACB","CBD","ARTL","BK4113","TMP","BK4007","BK4211"],"gpt_icon":0},{"id":"2516088125","title":"Avecho Signs Licensing Agreement with Swiss Off-Patient Medicine Provider","url":"https://stock-news.laohu8.com/highlight/detail?id=2516088125","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516088125?lang=en_us&edition=fundamental","pubTime":"2025-03-03 14:52","pubTimestamp":1740984752,"startTime":"0","endTime":"0","summary":"Avecho Biotechnology  has signed a ten-year exclusive licensing agreement with Switzerland-based Sandoz Group AG for the commercialization of its cannabidiol  capsule aimed at treating insomnia in Australia, according to a Monday filing with the Australian bourse.Under the deal, Avecho will receive an upfront payment of $3 million, milestone payments of up to $16 million, and royalties ranging from 14% to 19% on net sales, the filing said.Avecho will continue funding the ongoing Phase III clinical trial and collaborate with Sandoz on regulatory approval from the Therapeutic Goods Administration, the filing added.Once approved, Sandoz will market and distribute the product in Australia and Avecho will retain commercialization rights in all other territories, with Sandoz holding a right of first refusal, the company said.Shares of the company fell 14% on market close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","XJO.AU","CBD","XKO.AU","BK7096","AVE.AU","BK4113"],"gpt_icon":0},{"id":"2514375360","title":"IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…","url":"https://stock-news.laohu8.com/highlight/detail?id=2514375360","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514375360?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:07","pubTimestamp":1740737220,"startTime":"0","endTime":"0","summary":"Imunon, Inc.  is continuing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in patients with advanced ovarian cancer. IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin -12 expressing plasmid that allows for the durable, local, and targeted expression of IL-12 in the peritoneum. IL-12 is a potent pro-inflammatory cytokine that mediates a number of important cellular processes, including T cell and natural killer cell activation , the production of interferon-gamma , and alteration of myeloid-derived suppressor cells in the tumor microenvironment . While shown to be effective in pre-clinical tumor models, IL-12 therapy initially showed underwhelming results in the clinic along with very high levels of toxicity when administered systemically. This is likely due to the fact that the direct targets of IL-12 are not circulating lymphocytes, but rather immune cells located within the tumor and lymph nodes. Thus, while systemi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imnn-phase-3-ovarian-cancer-100700685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CBD","LU0054578231.USD","LU0149725797.USD","LU1363072403.SGD","IE00BZ1G4Q59.USD","BK4139","CMC","OS","LU0053671581.USD","BK4113","BK4161","LU0170899867.USD","IE00B1BXHZ80.USD","IMNN","IE00BHPRN162.USD","LU0882574139.USD","LU0267386448.USD","HR","BK4097","LU0971096721.USD","BK4006","BK4203","ITT","IE00BKVL7J92.USD","BK4225"],"gpt_icon":0},{"id":"2514733096","title":"Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2514733096","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514733096?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:01","pubTimestamp":1740690060,"startTime":"0","endTime":"0","summary":"BERWYN, Pa., February 27, 2025----Virpax Pharmaceuticals, Inc.  , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system  disorders and anti-viral barrier indications, would like to congratulate Nanomerics on completing a human study using the Molecular Envelope Technology  and showing no moderate to severe adverse events. Virpax uses MET in its Envelta  and NobrXiol.In addition, Virpax uses MET with NobrXiol. NobrXiol is being developed for delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utilizes the MET as its delivery system to cross the blood brain barrier, propelling the cannabidiol nanoparticles through the nose to the brain via the olfactory nerve. The drug has received pre-Investigational New Drug  application guidance from the U.S. Food and Drug Administration ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/virpax-reports-positive-results-human-210100424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","LU1291159041.SGD","IE00B29SXK94.USD","LU1496350502.SGD","LU1989772840.SGD","DOD","BK4007","MET","CBD","BK4585","IE00B29SXL02.USD","VRPX","BK4588","BK4113","LU1989772923.USD","CNS","LU1989771016.USD","BK4162"],"gpt_icon":0},{"id":"2514492832","title":"Ethereum Investors Capitalize During Dip, Accumulating Amidst Price Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2514492832","media":"BE[IN]CRYPTO","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514492832?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:30","pubTimestamp":1740573000,"startTime":"0","endTime":"0","summary":"Ethereum drops 11% to $2,486 but sees strong accumulation, with 786,660 ETH bought at $2,632, signaling investor confidence.Exchange outflows of 178,500 ETH  suggest long-term holding, reinforcing optimism despite Ethereum’s recent decline.ETH must reclaim $2,654 for recovery; failure could push the price down to $2,344, extending losses and delaying a breakout.Ethereum has recently struggled to maintain upward momentum after failing to break above the $2,800 resistance. The altcoin king’s price experienced a steep decline due to broader market bearish conditions, causing it to fall below $2,500.Despite the downturn, Ethereum investors have remained confident, seizing the opportunity to accumulate at lower price levels.However, if Ethereum fails to reclaim $2,654 and struggles under the weight of continued market bearishness, the price could dip further to $2,344. Such a scenario would extend losses and possibly invalidate the current bullish outlook, leaving investors awaiting cle","market":"us","thumbnail":"https://beincrypto.com/wp-content/uploads/2025/01/bic_ethereum_eth_1-covers_bullish-1-850x478.jpg.optimal.jpg","type":0,"news_type":0,"thumbnails":["https://beincrypto.com/wp-content/uploads/2025/01/bic_ethereum_eth_1-covers_bullish-1-850x478.jpg.optimal.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://beincrypto.com/ethereum-price-fall-acts-as-bane-for-investors/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"beincrypto_highlight","symbols":["ISBC","EZET","CETH","ETH.USD.HKCC","FETH","BK4211","CBD","BK4113","ETHV","LDO.USD.HKCC","QETH","ETH.USD.CC","BK4601","ETH"],"gpt_icon":0},{"id":"2514090203","title":"Xebra Brands Unveils Strategic Plan to Boost North American CBD Market Presence","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090203","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514090203?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:40","pubTimestamp":1740494410,"startTime":"0","endTime":"0","summary":"Xebra Brands Ltd. ( ($TSE:XBRA) ) has provided an update. Xebra Brands Ltd. has announced its Strategic 2025 Roadmap aimed at expanding its presenc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xebra-brands-unveils-strategic-plan-to-boost-north-american-cbd-market-presence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xebra-brands-unveils-strategic-plan-to-boost-north-american-cbd-market-presence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4117","BK4107","AFG","BK4557","ACB","CBD","BK4113","BK4007"],"gpt_icon":0},{"id":"2514609758","title":"TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2514609758","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514609758?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:20","pubTimestamp":1740493200,"startTime":"0","endTime":"0","summary":"Fully funded multi-center study initiated at University of Florida to further explore efficacy of isomyosamine for preventing progressive muscle loss and frailty. Study builds on positive results achieved in earlier Phase 2a trial. TNF-alpha inhibitor market estimated at $40+ billion with no FDA-approved oral treatments. \"The initiation of our Phase 2b isomyosamine trial marks an important milestone in our mission to develop a novel science for immuno-metabolic regulation and increased longevity,\" said Mitchell Glass, M.D., President and Chief Medical Officer of TNF. \"A deeper exploration of isomyosamine’s efficacy will be studied in patients with acute post-surgical inflammation and complications from hip or femur fractures. In addition to further functional decline, these patients face a higher likelihood of complications that can compromise or delay recovery and are associated with higher healthcare costs.\". Isomyosamine is an oral, next-generation TNF-α inhibitor with the potential","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-initiates-phase-2b-142000584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4557","CAGR","BK4159","ACB","CBD","BK4113","TNFA","BK4007"],"gpt_icon":0}],"pageSize":16,"totalPage":7,"pageCount":1,"totalSize":105}]}}